Holen Sie sich die Stockscreener-App
27.53
1.33%
-0.37
Schlusskurs vom Vortag:
$27.90
Offen:
$28.03
24-Stunden-Volumen:
975.14K
Relative Volume:
0.65
Marktkapitalisierung:
$5.69B
Einnahmen:
Nettoeinkommen (Verlust:
$-505.61M
KGV:
-9.9397
EPS:
-2.7697
Netto-Cashflow:
$-407.32M
1W Leistung:
-9.02%
1M Leistung:
-24.88%
6M Leistung:
+0.36%
1J Leistung:
+53.54%
1-Tages-Spanne:
$27.48
$28.33
1-Wochen-Bereich:
$27.83
$30.64
52-Wochen-Spanne:
$16.77
$45.42
Immunovant Inc Stock (IMVT) Company Profile
Firmenname
Immunovant Inc
Sektor
Branche
Telefon
917-410-3120
Adresse
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
27.53 | 5.69B | 0 | -505.61M | -407.32M | -2.7697 |
VRTX
Vertex Pharmaceuticals Inc
|
508.37 | 128.85B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
239.43 | 95.59B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
799.68 | 82.33B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
852.36 | 53.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
373.96 | 42.30B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-20 | Eingeleitet | Bernstein | Mkt Perform |
| 2026-01-06 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | Eingeleitet | Truist | Hold |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-03-03 | Eingeleitet | Jefferies | Hold |
| 2025-01-03 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-09 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-03-13 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | JP Morgan | Overweight |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-13 | Hochstufung | UBS | Neutral → Buy |
| 2023-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Eingeleitet | BofA Securities | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2023-02-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-08-03 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-01 | Herabstufung | Stifel | Buy → Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-12 | Eingeleitet | Guggenheim | Buy |
| 2020-10-08 | Eingeleitet | Stifel | Buy |
| 2020-10-02 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-24 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
Immunovant chief legal officer Van Tuyl sells $42,543 in stock By Investing.com - Investing.com South Africa
Immunovant chief legal officer Van Tuyl sells $42,543 in stock By Investing.com - Investing.com Canada
Immunovant COO Melanie Gloria sells shares worth $71,846 By Investing.com - Investing.com South Africa
Form 4 Immunovant Inc For: 9 October By Investing.com - Investing.com South Africa
Form 4 Immunovant Inc For: 9 October - Investing.com India
Immunovant COO Melanie Gloria sells shares worth $71,846 - Investing.com India
Immunovant CEO Eric Venker sells $119,589 in shares By Investing.com - Investing.com Nigeria
Form 4 Immunovant Inc For: 5 October By Investing.com - Investing.com South Africa
Immunovant CEO Eric Venker sells $119,589 in shares By Investing.com - Investing.com Canada
Form 4 Immunovant Inc For: 5 October By Investing.com - Investing.com Canada
Form 4 Immunovant Inc For: 5 October By Investing.com - Investing.com UK
Immunovant CLO Christopher Van Tuyl Executes Mandatory Sale of 2,846 Shares for Tax Withholding - Kalkine Media
How (IMVT) Movements Inform Risk Allocation Models - Stock Traders Daily
Immunovant Announces Voting Outcomes from 2026 Annual Stockholders Meeting - Kalkine Media
Immunovant (IMVT) Slips 0.94% to $39.12 as Shares Test Resistance at $41.08OBV Breakout - vinanet.vn
Roivant Sciences (ROIV) president sells 200,000 shares under preset plan - Stock Titan
Why (IMVT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Roivant (NASDAQ: ROIV) president settles RSU taxes in shares - Stock Titan
Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says - marketscreener.com
Immunovant (IMVT) Watch: Stays Close to Unchanged at $44.37; Technical Setup: Support at $42.15 and Resistance at $46.59 Frame the Range at the CloseBear Flag - vinanet.vn
Immunovant (IMVT) Watch: Stays Close to Unchanged at $44.37; Technical Setup: Support at $42.15 and Resistance at $46.59 Frame the Range at the CloseStraddle Setup - dars.gov.et
Deep Track Capital, LP Trims Immunovant Inc (IMVT) Stake in Stra - GuruFocus
Immunovant Inc GLP-1 Receptor Agonists Weight Management Diabetes Treatments *79wfgdDXy* - Villa de la Orotava
immunovant inc glp 1 receptor agonist diabetes weight managementView IiKNF3uia - Villa de la Orotava
Immunovant (IMVT) Results at a Glance: The Available Earnings Metric Delivers a Miss under the Current Snapshot; Post-Earnings: Shares Move Lower 1.98% in the Available RecordAnalyst Consensus Shift - vinanet.vn
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - Morningstar
Immunovant Inc GLP-1 Receptor Agonists Weight Management Diabetes Treatments *BI2Y6DHdO* - scchr.jp
Investigation launched into Immunovant officers for possible self-dealing harming shareholders - Pluang
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - PR Newswire
Immunovant (IMVT) Stock: Moves 1.49% Up to $44.96 in Latest Trading; Immediate View: Support at $42.71 and Resistance at $47.21 Frame the Range in the Latest ReadingPassive Flow - vinanet.vn
Immunovant (IMVT) Stock: Moves 1.49% Up to $44.96 in Latest Trading; Immediate View: Support at $42.71 and Resistance at $47.21 Frame the Range in the Latest ReadingSign of Strength - dars.gov.et
Immunovant (IMVT) Holds Steady at $41.82: Consolidation Between Key Support and ResistanceThematic ETF Flow - vinanet.vn
GSA Capital Partners LLP Takes $2.52 Million Position in Immunovant, Inc. $IMVT - MarketBeat
Assenagon Asset Management S.A. Has $639,000 Holdings in Immunovant, Inc. $IMVT - MarketBeat
Immunovant (IMVT) Holds Steady at $41.82 as Shares Consolidate in a Tight RangeGamma Exposure - vinanet.vn
Dimensional Fund Advisors LP Sells 103,356 Shares of Immunovant, Inc. $IMVT - MarketBeat
Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype - simplywall.st
Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype - simplywall.st
Immunovant (IMVT) Q1 2027 Earnings Call Transcript - AOL.com
Immunovant (NASDAQ:IMVT) Reaches New 12-Month HighShould You Buy? - MarketBeat
Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com Australia
Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com South Africa
Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com Nigeria
Immunovant stock hits 52-week high at 41.37 USD - Investing.com
Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com Canada
Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com India
Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com UK
The Manufacturers Life Insurance Company Cuts Stock Position in Immunovant, Inc. $IMVT - marketbeat.com
Immunovant, Inc. (IMVT) Stock Analysis: Assessing the 21% Potential Upside with Strong Analyst Confidence - DirectorsTalk Interviews
Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Finanzdaten der Immunovant Inc-Aktie (IMVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunovant Inc-Aktie (IMVT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Van Tuyl Christopher | Chief Legal Officer |
Oct 07 '26 |
Sale |
32.06 |
1,327 |
42,544 |
175,218 |
| Gloria Melanie | Chief Operating Officer |
Oct 07 '26 |
Sale |
32.06 |
2,241 |
71,846 |
217,060 |
| Venker Eric | Chief Executive Officer |
Oct 02 '26 |
Sale |
34.11 |
3,506 |
119,590 |
257,075 |
| Venker Eric | Chief Executive Officer |
Oct 01 '26 |
Option Exercise |
14.46 |
92,187 |
1,333,024 |
346,467 |
| Van Tuyl Christopher | Chief Legal Officer |
Sep 23 '26 |
Sale |
36.36 |
2,846 |
103,481 |
176,545 |
| Pande Atul | Director |
Aug 28 '26 |
Sale |
43.27 |
1,500 |
64,905 |
116,731 |
| Pande Atul | Director |
Aug 28 '26 |
Option Exercise |
8.43 |
1,500 |
12,645 |
118,231 |
| Gloria Melanie | Chief Operating Officer |
Aug 20 '26 |
Sale |
44.16 |
3,056 |
134,953 |
219,301 |
| Pande Atul | Director |
Jul 24 '26 |
Option Exercise |
8.43 |
1,500 |
12,645 |
118,231 |
| Pande Atul | Director |
Jul 24 '26 |
Sale |
39.80 |
1,500 |
59,700 |
116,731 |
0.49%
6.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):